|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis显示文摘瞄准:在有人半胱氨酸(HCY ) 和 haemostatic 系统的各种各样的部件的 PBC 和它的关系估计 hypercoagulability。方法:我们调查了 51 个 PBC 病人(43F/8M;意味着年龄:63+/-13.9 年) 并且 102 个健康题目(86 个 women/16 人;63+/-13 年) ,并且由 PFA-100 由 Sonoclot 分析和血小板功能在全血评估了 haemostatic 过程设备。我们然后测量了 HCY (禁食并且在蛋氨酸装载以后) ,织物因素(TF ) , thrombin-antithrombin 建筑群(梭织) , D 暗淡(D-D ) , thrombomodulin (TM ) , folic,维生素 B6 和 B12 血浆铺平。C677T 5,10-methylenetetrahydrofolate 还原酶(MTHFR ) 多型性被分析。结果:病人的 Sonoclot 率值是显著地(P<0.001 ) 比那些高控制。山峰价值的 Sonoclot 时间和 PFA-100 闭合时间在病人和控制是可比较的。梭织, TF 和 HCY 层次,两个在禁食并且蛋氨酸以后的装载,显著地(P<0.001 ) 在病人更高与比在控制。维生素缺乏在 45/51 病人(88.2%) 被检测。同型结合的 TT677 MTHFR 遗传型的流行比在控制(17.5%)(P<0.05 ) 在病人(31.4%) 是显著地更高的。Sonoclot 率价值与 HCY 层次和 TF 显著地相关。结论:在 PBC, hyper-HCY 与维生素缺少和基因预先安排因素有关。内皮激活的增加的 TF 和 HCY 层次和符号与 hypercoagulability 被联系并且可以在血凝固激活有一个重要角色。 | Maria Rosa Biagini Alessandro Tozzi Rossella Marcucci Rita Paniccia Sandra Fedi Stefano Milani Andrea Galli Elisabetta Ceni Marco Capanni Raffaele Manta Rosanna Abbate Calogero Surrenti | 2006 | World Journal of Gastroenterology2006，12，10： | 6 |
| 2 | Resectable Pancreatic Cancer: Who Really Benefits From Resection?显示文摘 | Giuliano Barugola MD Stefano Partelli MD Stefano Marcucci MD Nora Sartori MD Paola Capelli MD Claudio Bassi MD Paolo Pederzoli MD Massimo Falconi MD | 2009 | Annals of Surgical Oncology2009，，12： | 2 |
| 3 | Resectable Pancreatic Cancer: Who Really Benefits From Resection?显示文摘 | Giuliano Barugola Stefano Partelli Stefano Marcucci Nora Sartori Paola Capelli Claudio Bassi Paolo Pederzoli Massimo Falconi | 2009 | Annals of Surgical Oncology2009，，： | 1 |
| 4 | Comp- lications after pancreaticoduodenectomy: the problem of current definitions显示文摘 | Giovanni Butturini Stefano Marcucci Enrico Molinari | 2006 | Journal of Hepato - Biliary - Pancreatic Surgery2006，13，3： | 1 |
| 5 | Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives显示文摘Although gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs)have always been considered rare tumors,their incidence has risen over the past few decades.They represent a highly heterogeneous group of neoplasms with several prognostic factors,including disease stage,proliferative index(Ki67),and tumor differentiation.Most of these neoplasms express somatostatin receptors on the cell surface,a feature that has important implications in terms of prognosis,diagnosis,and therapy.Although International Guidelines propose algorithms aimed at guiding therapeutic strategies,GEP-NEN patients are still very different from one another,and the need for personalized treatment continues to increase.Radical surgery is always the best option when feasible;however,up to 80%of cases are metastatic upon diagnosis.Regarding medical treatments,as GEP-NENs are characterized by relatively long overall survival,multiple therapy lines are adopted during the lifetime of these patients,but the optimum sequence to be followed has never been clearly defined.Furthermore,although new molecular markers aimed at predicting the response to therapy,as well as prognostic scores,are currently being studied,their application is still far from being part of daily clinical practice.As they represent a complex disease,with therapeutic protocols that are not completely standardized,GEP-NENs require a multidisciplinary approach.This review will provide an overview of the available therapeutic options for GEP-NENs and attempts to clarify the possible approaches for the management of these patients and to discuss future perspectives in this field. | Elettra Merola Andrea Michielan Umberto Rozzanigo Marco Erini Sandro Sferrazza Stefano Marcucci Chiara Sartori Chiara Trentin Giovanni de Pretis Franca Chierichetti | 2022 | World Journal of Gastrointestinal Surgery2022，14，2： | 1 |
| 6 | Prognostic Relevance of Lymph Node Ratio and Number of Resected Nodes after Curative Resection of Ampulla of Vater Carcinoma显示文摘 | Massimo Falconi Stefano Crippa Ismael Domínguez Giuliano Barugola Paola Capelli Stefano Marcucci Stefania Beghelli Aldo Scarpa Claudio Bassi Paolo Pederzoli | 2008 | Annals of Surgical Oncology2008，，11： | 1 |
| 7 | Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase 显示文摘 | Camacho Vanegas O Giusti B Brunelli T Marcucci R Attanasio M Rickard O De Stefano GF Prisco D Gensini GF Abbate R | 1998 | Am J Hum Genet1998，63，3： | 1 |
| 8 | Resectable Pancreatic Cancer: Who Really Benefits From Resection?显示文摘 | Giuliano Barugola MD Stefano Partelli MD Stefano Marcucci MD Nora Sartori MD Paola Capelli MD Claudio Bassi MD Paolo Pederzoli MD Massimo Falconi MD | 2009 | Annals of Surgical Oncology2009，，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员